ARQT logo

ARQT
Arcutis Biotherapeutics Inc

2,512
Mkt Cap
$3.56B
Volume
2.22M
52W High
$31.77
52W Low
$11.13
PE Ratio
-81.86
ARQT Fundamentals
Price
$29.02
Prev Close
$29.47
Open
$29.35
50D MA
$25.05
Beta
1.38
Avg. Volume
2.67M
EPS (Annual)
-$1.16
P/B
22.08
Rev/Employee
$574,684.21
Loading...
Loading...
News
all
press releases
Arcutis Biotherapeutics, Inc. $ARQT Holdings Boosted by Frazier Life Sciences Management L.P.
Frazier Life Sciences Management L.P. boosted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 12.4% in the second quarter, according to the company in its most...
MarketBeat·19h ago
News Placeholder
More News
News Placeholder
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to Strong-Buy at Wall Street Zen
Wall Street Zen raised Arcutis Biotherapeutics from a "buy" rating to a "strong-buy" rating in a research note on Sunday...
MarketBeat·1d ago
News Placeholder
Gilder Gagnon Howe & Co. LLC Purchases 59,712 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Gilder Gagnon Howe & Co. LLC increased its position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 1.5% in the 2nd quarter, according to the company in its most recent disclosure...
MarketBeat·2d ago
News Placeholder
Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest
read more...
Benzinga·4d ago
News Placeholder
Norges Bank Takes $2.45 Million Position in Arcutis Biotherapeutics, Inc. $ARQT
Norges Bank purchased a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the second quarter, according to its most recent disclosure with the Securities and...
MarketBeat·4d ago
News Placeholder
What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now?
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·5d ago
News Placeholder
Stempoint Capital LP Sells 334,401 Shares of Arcutis Biotherapeutics, Inc. $ARQT
Stempoint Capital LP lowered its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 61.9% in the second quarter, according to its most recent 13F filing with the SEC...
MarketBeat·5d ago
News Placeholder
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.7% - What's Next?
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4.7% - Time to Sell...
MarketBeat·5d ago
News Placeholder
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.
Zacks·7d ago
News Placeholder
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Zacks·7d ago

Latest ARQT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.